Monday will be remembered as the day T-cell engagers crossed from oncology curiosity into absolute autoimmune conviction. Gilead Sciences and Sanofi, on the exact same day, committed a combined $3 billion in upfront and milestone payments to acquire or license early-stage T-cell engager assets targeting B-cell depletion in autoimmune disease. Gilead is paying $1.675 billion upfront to acquire Ouro Medicines and its BCMAxCD3 bispecific gamgertamig, which demonstrated “transformative efficacy” after a single subcutaneous treatment cycle in autoimmune hemolytic anemia and immune thrombocytopenia. Hours later, Sanofi announced it had licensed Kali Therapeutics’ trispecific T-cell engager KT501 for $180 million upfront and up to $1.05 billion in milestones. Two major pharma companies. The exact same mechanism class. The exact same day. This is no longer a trend—it is a strategic consensus that the autoimmune treatment paradigm is about to change.
Top Story: Gilead Bets $1.675B on the Autoimmune Reset
What Happened: Gilead Sciences announced a definitive agreement to acquire Ouro Medicines, a privately held biotech developing T-cell engager therapies for autoimmune diseases, for $1.675 billion upfront in cash plus up to $500 million in contingent milestones.
The Asset: Gamgertamig (OM336)
The deal centers on OM336 (gamgertamig), a clinical-stage BCMAxCD3 bispecific T-cell engager designed to enable rapid, deep B-cell depletion after a limited subcutaneous treatment course. In ongoing Phase 1/2 studies, OM336 demonstrated what Gilead described as “transformative efficacy and a differentiated safety profile” after a single treatment cycle in autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP).
Understanding the Autoimmune Reset Thesis
To appreciate why Gilead wrote a $1.675 billion check for a Phase 1/2 asset, it helps to understand the fundamental limitation of current autoimmune therapy and what T-cell engagers could change.
Today’s standard of care for most autoimmune diseases is chronic immunosuppression. Patients take drugs—biologics, small molecules, or steroids—that dampen the immune system broadly, often for life. These therapies manage symptoms and slow progression, but they do not address the root cause: the pathogenic B cells and long-lived plasma cells that produce the autoantibodies driving the disease. When patients stop therapy, the disease almost invariably returns because the underlying immune memory remains intact.
T-cell engagers offer a fundamentally different approach. These bispecific antibodies physically bridge a patient’s own T cells to the pathogenic B cells and plasma cells, directing the immune system to eliminate them. By targeting BCMA—a marker expressed on the long-lived plasma cells that are the deepest reservoir of autoimmune memory—OM336 aims to achieve a level of immune depletion that goes far beyond what anti-CD20 antibodies like rituximab can accomplish.
The theoretical endgame is durable remission without ongoing therapy. A short treatment course depletes the pathogenic immune cells, and when the immune system reconstitutes, it does so without the autoimmune programming that was driving the disease. If this works—and “if” remains the operative word at Phase 1/2—it represents a paradigm shift from chronically managing autoimmune disease to functionally resetting the immune system.
The Galapagos Dimension
Gilead is in advanced discussions with Galapagos (GLPG) for a 50/50 collaboration on the Ouro portfolio. Under the contemplated terms, Galapagos would pay half the upfront consideration and half of any milestone payments, with royalties of 20-23% of net sales. This is a potentially significant development for a Gilead-Galapagos partnership that had been widely viewed as directionless since the original $5.1 billion investment in 2019. If the collaboration is finalized, it would give Galapagos exposure to one of the most watched asset classes in immunology and inject genuine strategic purpose into a relationship that has underdelivered for years.
Gilead’s Broader Autoimmune Buildout
This is Gilead’s second major acquisition in a month, following the $7.8 billion Arcellx deal for CAR-T cell therapy. The pattern reveals a deliberate strategy: Gilead is building a two-modality autoimmune franchise that pairs CAR-T for deep immune reconstitution in the most severe patients with T-cell engagers for shorter-course immune depletion in broader populations.
These are not competing approaches. CAR-T is autologous, deeply personalized, and potentially curative for the most refractory patients—but constrained by manufacturing complexity, logistical burden, and cost. T-cell engagers are off-the-shelf, subcutaneous, and designed for dramatically broader accessibility. Gilead is betting that it can own the full continuum of “immune reset” in autoimmune disease, from the most accessible modality to the most potent. No other major pharma company is assembling this exact combination in-house.
Our Pro brief includes a full analysis of Gilead’s two-modality strategy, including how CAR-T and TCEs create complementary coverage across severity segments and what this means for competitive positioning against BMS, Roche, and AbbVie. [Details below.]
What to Watch
Registrational studies for OM336 are expected to start in 2027. Interim Phase 1/2 data later in 2026 will be the next major clinical catalyst—specifically, durability of response data and the cytokine release syndrome (CRS) profile in a larger patient sample. The Galapagos collaboration terms are still being finalized; the formal agreement will clarify economics and development responsibilities.
Sanofi Returns to T-Cell Engagers with $1.23B Kali Deal
What Happened: Sanofi signed an exclusive worldwide license agreement with Kali Therapeutics for KT501, a trispecific T-cell engager that simultaneously targets CD3, CD19, and BCMA on B-lineage cells. Kali receives $180 million upfront, with up to $1.05 billion in milestones plus tiered royalties.
The Trispecific Approach: Three Targets, One Molecule
KT501 is not a standard bispecific. By engaging CD3 (on T cells), CD19 (on B cells), and BCMA (on plasma cells) simultaneously, the trispecific design aims to eliminate pathogenic B cells across their entire maturation spectrum in a single molecule. Standard dual-target bispecifics typically hit one B-cell marker plus CD3, which can leave portions of the B-cell lineage intact. The trispecific approach bets that hitting both CD19 and BCMA simultaneously will produce deeper, more durable depletion—closing the escape routes that residual B-cell populations might exploit.
Kali’s proprietary CD3 masking platform adds another layer of differentiation. The masking technology is designed to decouple potency from toxicity by keeping the CD3-binding arm inactive until the molecule engages its B-cell targets. This aims to maximize B-cell depletion while minimizing the cytokine release syndrome that has been the primary safety concern with T-cell engagers across both oncology and autoimmune applications.
Sanofi’s Strategic Context
This deal marks Sanofi’s aggressive return to the T-cell engager space after the company sold three clinical-stage TCEs to Vir Biotechnology in 2024—a transaction that was widely interpreted as a retreat from the mechanism. The KT501 license reverses that signal emphatically, and it arrives in the context of a broader immunology spending spree that has accelerated dramatically since the CEO transition.
KT501 just entered a Phase 1 trial in adults with moderately to severely active rheumatoid arthritis this month, with estimated completion in August 2027. Initial safety and pharmacodynamic data—particularly the depth of B-cell depletion achieved and the CRS profile under the masking platform—will be critical to validate the trispecific mechanism.
Our Pro brief tracks Sanofi’s cumulative immunology dealmaking since the CEO change, totaling approximately $14 billion in committed capital across four major transactions in roughly 12 months. We assess what this spending velocity signals about strategic urgency versus pipeline confidence. [Details below.]
What to Watch
The Phase 1 data readout, expected in late 2027, will be the definitive validation point. If KT501 demonstrates the safety advantage its masking platform promises alongside deep B-cell depletion, Sanofi will have secured a differentiated position in the T-cell engager race. If the trispecific mechanism introduces unexpected complexity—off-target engagement, unpredictable pharmacokinetics, or inadequate masking—the $1.23 billion total deal value becomes a high-profile cautionary example.
Clinical & Research Updates
Vaxcyte Completes Pivotal Pneumococcal Vaccine Enrollment
Vaxcyte announced the completion of enrollment in both OPUS-1 and OPUS-2, its Phase 3 trials evaluating VAX-31, a 31-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease and pneumonia in adults.
Why This Matters: VAX-31 covers significantly more serotypes than the current market leaders—Pfizer’s Prevnar 20 (20-valent) and Merck’s Vaxneuvance (15-valent). Completing enrollment in both pivotal trials simultaneously is a meaningful de-risking event for Vaxcyte, as it removes the execution uncertainty around recruitment timelines. The broader serotype coverage, if it translates to superior immunogenicity and clinical protection, would position VAX-31 as a next-generation replacement for the established franchises.
The pneumococcal vaccine market is substantial—Prevnar 20 generated more than $6 billion in 2025 revenue for Pfizer—and a 31-valent competitor that demonstrates superior coverage would have immediate commercial relevance. Topline data timing will be the next major catalyst.
Lexicon and Novo Nordisk Initiate Phase 1 of Oral Obesity Drug
Lexicon Pharmaceuticals and Novo Nordisk announced the initiation of a Phase 1 study for LX9851, an oral obesity drug candidate being developed under their collaboration.
Why This Matters: The oral obesity space is getting more crowded by the quarter. LX9851 adds another entrant alongside Lilly’s orforglipron (April 10 PDUFA), Novo’s own oral Wegovy (already on market), and multiple earlier-stage candidates. While the Novo partnership lends credibility, LX9851 is years behind the leading oral programs and is not yet a material competitive factor. It is worth tracking as a signal of Novo’s continued investment in oral metabolic innovation beyond semaglutide.
Strategic Themes
1. The Autoimmune Treatment Paradigm Is at a Genuine Inflection Point
Two companies committing $3 billion to the same mechanism class on the same day is not a coincidence—it is a coordinated market signal that the largest pharmaceutical companies believe T-cell engagers can fundamentally change how autoimmune disease is treated. The shift from chronic suppression to immune reset, if clinically validated, would restructure the economics of autoimmune medicine. Instead of lifetime therapy generating recurring revenue, the industry would move toward short-course treatments that produce durable remission. That is transformative for patients and deeply disruptive for the companies currently generating tens of billions annually from chronic immunosuppressive franchises.
2. The Risk Is Proportional to the Conviction
Gilead paid $1.675 billion upfront for Phase 1/2 data from a handful of patients. Sanofi committed up to $1.23 billion for a drug that entered Phase 1 this month. The clinical evidence supporting both deals is extraordinarily thin relative to the capital deployed. Durability of responses, CRS risk in non-oncology populations, long-term safety of deep B-cell depletion, and the fundamental question of whether immune reconstitution truly “resets” without autoimmune recurrence—all remain massive open questions. The institutional conviction is real, but the gap between conviction and clinical proof is wide.
3. Gilead Is Building Something No Competitor Can Easily Replicate
The combination of CAR-T (via Arcellx/Kite) and T-cell engagers (via Ouro) gives Gilead a two-modality autoimmune platform that covers the full severity spectrum. CAR-T for the most refractory patients who need maximum-intensity intervention. TCEs for the broader population where off-the-shelf, subcutaneous delivery makes deep B-cell depletion accessible at scale. No other large pharma company is assembling both modalities under one roof for autoimmune disease. If the clinical data validates both approaches, Gilead’s competitive moat in immune reset medicine will be substantial.
4. Sanofi’s Dealmaking Velocity Raises Both Opportunity and Execution Questions
The cumulative immunology spending since the CEO transition—multiple billions committed across several major transactions—signals an organization that has identified immunology as its strategic centerpiece and is willing to pay premium prices to secure platform assets before competitors lock them up. The opportunity is clear: if even one or two of these bets pay off, Sanofi rebuilds its immunology franchise for the next decade. The risk is equally clear: this volume of early-stage spending creates concentrated write-off exposure, and the integration demands of absorbing multiple novel technology platforms simultaneously are not trivial.
Frequently Asked Questions
What is a T-cell engager, and why does it matter for autoimmune disease?
A T-cell engager is a bispecific or trispecific antibody that physically bridges a patient’s T cells to target cells—in this case, pathogenic B cells and plasma cells that drive autoimmune disease. By directing the immune system to eliminate these cells through a short treatment course, T-cell engagers aim to achieve durable immune “reset” rather than chronic suppression. If the approach works, patients could achieve remission without ongoing therapy, fundamentally changing the treatment paradigm for diseases like lupus, rheumatoid arthritis, and autoimmune blood disorders.
What is the difference between Gilead’s OM336 and Sanofi’s KT501?
OM336 is a bispecific that targets BCMA and CD3, focusing on depleting long-lived plasma cells. KT501 is a trispecific that targets CD3, CD19, and BCMA simultaneously, aiming to eliminate B cells across their entire maturation spectrum in a single molecule. KT501 also incorporates a CD3 masking platform designed to reduce cytokine release syndrome. Both target B-cell depletion for autoimmune reset, but through mechanistically distinct approaches with different risk-benefit profiles.
Why did Gilead pay $1.675 billion for a Phase 1/2 asset?
The price reflects institutional conviction that T-cell engagers represent a paradigm shift in autoimmune treatment. OM336 demonstrated what Gilead called “transformative efficacy” after a single subcutaneous treatment cycle in AIHA and ITP. The asset also fits Gilead’s broader strategy of building a two-modality autoimmune franchise alongside CAR-T (from the $7.8B Arcellx acquisition). The premium reflects both the therapeutic potential and the competitive urgency to secure platform assets before rivals.
What is the Galapagos angle in the Gilead deal?
Gilead is in advanced discussions with Galapagos for a 50/50 collaboration on the Ouro portfolio, where Galapagos would pay half the upfront and milestone costs in exchange for 20-23% royalties on net sales. If finalized, this would give the long-underperforming Gilead-Galapagos partnership genuine strategic purpose for the first time since the original $5.1 billion investment in 2019.
Why did Sanofi sell its TCEs in 2024 and then buy back into the space?
Sanofi sold three clinical-stage T-cell engagers to Vir Biotechnology in 2024, which was widely interpreted as a strategic retreat from the mechanism. The KT501 license reverses that signal. The distinction may be generational: the assets Sanofi sold were earlier-generation TCEs, while KT501 incorporates a proprietary CD3 masking platform and trispecific design that addresses the cytokine release syndrome concerns that limited earlier approaches. Sanofi appears to be betting that next-generation TCE technology resolves the safety challenges that made earlier versions less attractive.
What is Vaxcyte’s VAX-31, and why does enrollment completion matter?
VAX-31 is a 31-valent pneumococcal conjugate vaccine—covering significantly more bacterial serotypes than Pfizer’s Prevnar 20 (20-valent) or Merck’s Vaxneuvance (15-valent). Completing enrollment in both pivotal Phase 3 trials removes execution uncertainty around recruitment timelines and positions Vaxcyte for topline data readouts. The pneumococcal vaccine market exceeds $6 billion annually, and a next-generation product with broader coverage would have significant commercial potential.
How does the oral obesity landscape look with the Lexicon/Novo Phase 1?
LX9851 adds another entrant to an increasingly crowded oral obesity field, but it is years behind the leaders. Lilly’s orforglipron faces an April 10 PDUFA, Novo’s oral Wegovy is already on market, and multiple other candidates are in various stages of development. The Novo partnership adds credibility, but LX9851 is not a material competitive factor at the Phase 1 stage.
What should investors watch at ACC.26 this weekend?
The American College of Cardiology meeting (March 28-30 in New Orleans) will feature cardiovascular outcomes data, including cardio-metabolic crossover presentations relevant to the GLP-1 and metabolic space. With Wegovy HD just launched, retatrutide in Phase 3, and orforglipron pending, any cardiovascular outcomes data connected to metabolic therapies will be closely scrutinized. Rocket Pharma’s Kresladi PDUFA also lands on March 28, overlapping with the conference opening.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
The Autoimmune Reset Thesis — Fully Unpacked. We analyze why two $1B+ T-cell engager deals on the same day signals a structural inflection for autoimmune medicine, what the theoretical endgame of immune reset means for the $100B+ chronic immunosuppression market, and where the clinical evidence still falls short of the institutional conviction.
Gilead’s Two-Modality Playbook. CAR-T plus T-cell engagers creates a severity-spectrum strategy that no competitor is replicating. We map how these modalities complement each other across patient populations and assess what it means for Gilead’s competitive positioning against BMS, Roche, and AbbVie in autoimmune disease.
Sanofi’s $14B Immunology Spending Spree. We track the cumulative dealmaking since the CEO transition—Blueprint, Dren, Sino Biopharma, and now Kali—and assess whether this velocity reflects strategic confidence or pipeline desperation. The write-off risk math on this much early-stage capital is sobering.
Plus: Rocket Pharma PDUFA probability framing, ACC.26 sessions worth tracking, and the updated catalyst calendar through mid-2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
